Fig. 7From: Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseIbrutinib-regulated pathways in immune cells. a UMAP representation of T cytotoxic signature in immune cells under ibrutinib treatment. b Cell quantification according to cytotoxic, activation and exhaustion gene scores c Percent of CD69 or PD1 expressing cells quantified by ADT-labelingBack to article page